DK3630729T3 - Pyrimidinforbindelse - Google Patents

Pyrimidinforbindelse Download PDF

Info

Publication number
DK3630729T3
DK3630729T3 DK18732930.5T DK18732930T DK3630729T3 DK 3630729 T3 DK3630729 T3 DK 3630729T3 DK 18732930 T DK18732930 T DK 18732930T DK 3630729 T3 DK3630729 T3 DK 3630729T3
Authority
DK
Denmark
Prior art keywords
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
DK18732930.5T
Other languages
English (en)
Inventor
Tomoichi Shinohara
Shin Iwata
Kenta Arai
Nobuaki Ito
Masaki Suzuki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK3630729T3 publication Critical patent/DK3630729T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18732930.5T 2017-05-31 2018-05-31 Pyrimidinforbindelse DK3630729T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2017/020322 WO2018220762A1 (ja) 2017-05-31 2017-05-31 ピリミジン化合物
PCT/JP2018/020997 WO2018221667A1 (en) 2017-05-31 2018-05-31 Pyrimidine compound

Publications (1)

Publication Number Publication Date
DK3630729T3 true DK3630729T3 (da) 2021-12-13

Family

ID=62685028

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18732930.5T DK3630729T3 (da) 2017-05-31 2018-05-31 Pyrimidinforbindelse

Country Status (24)

Country Link
US (3) US10800758B2 (da)
EP (1) EP3630729B1 (da)
JP (1) JP6739653B2 (da)
KR (2) KR102688531B1 (da)
CN (1) CN110603248B (da)
AU (1) AU2018277949B2 (da)
BR (1) BR112019023988A2 (da)
CA (1) CA3064176A1 (da)
CY (1) CY1125073T1 (da)
DK (1) DK3630729T3 (da)
EA (1) EA038907B1 (da)
ES (1) ES2901452T3 (da)
HR (1) HRP20211913T1 (da)
HU (1) HUE056942T2 (da)
IL (1) IL270579B2 (da)
LT (1) LT3630729T (da)
MX (1) MX2019014384A (da)
PH (1) PH12019502639A1 (da)
PL (1) PL3630729T3 (da)
PT (1) PT3630729T (da)
SA (1) SA519410563B1 (da)
SI (1) SI3630729T1 (da)
TW (1) TWI808974B (da)
WO (2) WO2018220762A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6870064B2 (ja) * 2018-11-30 2021-05-12 大塚製薬株式会社 ピリミジン化合物の医薬用途
CN113166076A (zh) * 2018-11-30 2021-07-23 大塚制药株式会社 用于治疗癫痫的杂环化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249812A1 (en) * 2002-07-18 2004-02-09 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
CA2781685C (en) * 2009-12-11 2018-09-04 Autifony Therapeutics Limited Imidazolidinedione derivatives
MX2012008346A (es) * 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
EP2649066B1 (en) 2010-12-06 2015-10-21 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
CN103596943B (zh) 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
MX2014001088A (es) * 2011-07-28 2015-03-19 Chdi Foundation Inc Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
PL2788339T3 (pl) * 2011-12-06 2016-09-30 Pochodne hydantoiny przydatne jako inhibitory KV3
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses

Also Published As

Publication number Publication date
WO2018221667A1 (en) 2018-12-06
AU2018277949A1 (en) 2019-12-12
US10800758B2 (en) 2020-10-13
TWI808974B (zh) 2023-07-21
BR112019023988A2 (pt) 2020-06-30
PH12019502639A1 (en) 2020-06-08
EP3630729A1 (en) 2020-04-08
WO2018220762A1 (ja) 2018-12-06
US20230138411A1 (en) 2023-05-04
EA038907B1 (ru) 2021-11-08
KR20240116588A (ko) 2024-07-29
JP2020503334A (ja) 2020-01-30
HRP20211913T1 (hr) 2022-03-04
US20200399245A1 (en) 2020-12-24
IL270579A (da) 2019-12-31
MX2019014384A (es) 2020-01-23
CA3064176A1 (en) 2018-12-06
HUE056942T2 (hu) 2022-03-28
ES2901452T3 (es) 2022-03-22
CN110603248B (zh) 2023-07-04
EP3630729B1 (en) 2021-11-03
IL270579B1 (en) 2023-04-01
KR20200011962A (ko) 2020-02-04
SA519410563B1 (ar) 2022-07-25
CN110603248A (zh) 2019-12-20
US20200017476A1 (en) 2020-01-16
SI3630729T1 (sl) 2022-01-31
PT3630729T (pt) 2021-12-16
PL3630729T3 (pl) 2022-01-24
TW202346283A (zh) 2023-12-01
KR102688531B1 (ko) 2024-07-26
EA201992831A1 (ru) 2020-03-30
LT3630729T (lt) 2022-01-10
CY1125073T1 (el) 2023-03-24
TW201902890A (zh) 2019-01-16
AU2018277949B2 (en) 2021-11-18
JP6739653B2 (ja) 2020-08-12
IL270579B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
DK3360864T3 (da) Pyrimidinforbindelse
DK3731771T3 (da) V462033dk00
DK3436444T3 (da) Heterocyklisk forbindelse
DE202018003363U8 (de) Handgelenkssphygmomanometer
CL2018000524S1 (es) Golilla
DK3351526T3 (da) Diisopentylterephthalat
DK3612519T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
DK3387930T3 (da) Stofanordning
DK3568655T3 (da) Rekuperator
DK3395821T3 (da) Antitumorforbindelser
DK3612237T3 (da) Genterapi
DK3568506T3 (da) Offeranode
DK3347403T3 (da) Polyalkoxyfedtforbindelse
DK3372589T3 (da) Pyrimidinderivat
DK3672941T3 (da) Pyridylpyridonforbindelser
DK3576686T3 (da) Brokbind
DK3630729T3 (da) Pyrimidinforbindelse
DK3676276T3 (da) Spirothietannukleosider
DK3395159T3 (da) Ballepresse
DK3576718T3 (da) Pastil
DK3672962T3 (da) Morpholinylpyridonforbindelser
DK3510051T3 (da) Carboxylalkylchitosan
DK3391733T3 (da) Ballepresse
ES1205411Y (es) Maleta-Gaveta